Segmental Urethral Dosimetry and Urinary Toxicity in Patients With No Urinary Symptoms Before Permanent Prostate Brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 2, 2008, Pages 447-455

  Thomas, Carys ^a   Keyes, Mira ^a   Liu, Mitchell ^b   Moravan, Veronika ^c  

^a Vancouver Cancer Centre   (Canada)

^b Fraser Valley Cancer Centre   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Prostate brachytherapy; Urethral dosimetry; Urinary toxicity

Indexed keywords

DECISION MAKING; FORECASTING; IODINE; MULTIVARIANT ANALYSIS; NEEDLES; RANDOM VARIABLES; REGRESSION ANALYSIS; TOXICITY;

PROSTATE BRACHYTHERAPY; URETHRAL DOSIMETRY; URINARY MORBIDITY; URINARY TOXICITY;

DOSIMETRY;

IODINE 125;

ADULT; AGED; ARTICLE; BLADDER CATHETERIZATION; BRACHYTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOSIMETRY; FOLLOW UP; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; ULTRASOUND; URINARY TRACT OBSTRUCTION; URINE RETENTION;

AGED; ANALYSIS OF VARIANCE; BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; URETHRA; URETHRAL OBSTRUCTION; URINARY CATHETERIZATION;

EID: 51449118374     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.12.052     Document Type: Article

References (35)

1. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
2. Nag S., Ellis R.J., Merrick G.S., et al. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 54 (2002) 462-470
3. Allen Z.A., Merrick G.S., Butler W.M., et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys 62 (2005) 981-987
4. Keyes M., Schellenberg D., Moravan V., et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?. Int J Radiat Oncol Biol Phys 64 (2006) 825-834
5. Keyes M., Miller S., Morvan V., et al. Acute and late urinary toxicity in 606 brachytherapy patients-The BC Cancer Agency Experience. Brachytherapy 6 (2007) 91
6. Wallner K., Roy J., and Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 32 (1995) 465-471
7. Desai J., Stock R.G., Stone N.N., et al. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Investig 6 (1998) 135-141
8. Neill M., Le L., Studer G., et al. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry. Brachytherapy 6 (2007) 105
9. Bucci J., Morris W.J., Keyes M., et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 53 (2002) 91-98
10. Terk M.D., Stock R.G., and Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 160 (1998) 1379-1382
11. Crook J., McLean M., Catton C., et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 453-460
12. Elshaikh M.A., Angermeier K., Ulchaker J.C., et al. Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy. Urology 61 (2003) 152-155
13. Locke J., Ellis W., Wallner K., et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study. Int J Radiat Oncol Biol Phys 52 (2002) 712-719
14. Elshaikh M.A., Ulchaker J.C., Reddy C.A., et al. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: Final report of a double-blind placebo-controlled randomized study. Int J Radiat Oncol Biol Phys 62 (2005) 164-169
15. Merrick G.S., Butler W.M., Wallner K.E., et al. Long-term urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 56 (2003) 454-461
16. Merrick G.S., Butler W.M., Tollenaar B.G., et al. The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys 52 (2002) 461-468
17. Cesaretti J.A., Stone N.N., and Stock R.G. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 56 (2003) 1085-1092
18. Merrick G.S., Butler W.M., Wallner K.E., et al. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy. Brachytherapy 3 (2004) 22-29
19. Thomas C., Bainbridge T., Thomson T., et al. Clinical Impact of second pathology opinion: A longitudinal study of central pathology review before prostate brachytherapy. Brachytherapy 6 (2007) 135-141
20. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 12 (2002) 81-94
21. Macdonald A.G., Keyes M., Kruk A., et al. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important?. Int J Radiat Oncol Biol Phys 63 (2005) 155-163
22. Bucci J., Spadinger I., Hilts M., et al. Urethral and periurethral dosimetry in prostate brachytherapy: Is there a convenient surrogate?. Int J Radiat Oncol Biol Phys 54 (2002) 1235-1242
23. Merrick G.S., Butler W.M., Wallner K.E., et al. The impact of radiation dose to the urethra on brachytherapy-related dysuria. Brachytherapy 4 (2005) 45-50
24. Andreassen C.N., Alsner J., Overgaard M., et al. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 69 (2003) 127-135
25. Cesaretti J.A., Stock R.G., Lehrer S., et al. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys 61 (2005) 196-202
26. Moullan N., Cox D.G., Angele S., et al. Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 12 (2003) 1168-1174
27. Quarmby S., Fakhoury H., Levine E., et al. Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol 79 (2003) 137-143
28. Severin D.M., Leong T., Cassidy B., et al. Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. Int J Radiat Oncol Biol Phys 50 (2001) 1323-1331
29. Sidhu S., Morris W.J., Spadinger I., et al. Prostate brachytherapy postimplant dosimetry: A comparison of prostate quadrants. Int J Radiat Oncol Biol Phys 52 (2002) 544-552
30. Thomas C., Kruk A., McGahan C., et al. Prostate brachytherapy post-implant dosimetry: A comparison between higher and lower source density. Radiother Oncol 83 (2007) 18-24
31. D'Amico A.V., Davis A., Vargas S.O., et al. Defining the implant treatment volume for patients with low risk prostate cancer: Does the anterior base need to be treated?. Int J Radiat Oncol Biol Phys 43 (1999) 587-590
32. Vargas S.O., Jiroutek M., D'Amico A.V., et al. Distribution of carcinoma in radical prostatectomy specimens in the era of serum prostate-specific antigen testing: Implications for delivery of localized therapy. Am J Clin Pathol 112 (1999) 373-376
33. Merrick G., Gutman S., Adamovich E., et al. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy: Implications for brachytherapy treatment planning. Brachytherapy 6 (2007) 93
34. Lee H.K., D'Souza W.D., Yamal J.M., et al. Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 57 (2003) 355-361
35. Roach III M., Faillace-Akazawa P., Malfatti C., et al. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 35 (1996) 1011-1018